Pazopanib in clear cell sarcoma therapy Case report

Article Sidebar

PDF


Published: Mar 14, 2018
DOI: https://doi.org/10.24292/01.OR.140318
Keywords:
soft-tissue sarcoma, clear cell sarcoma, pazopanib

Main Article Content

Katarzyna Kryszczyszyn-Musialik
1. Oncology Department with Hematological Subdivision, Provincial Specialist Hospital No. 3 in Rybnik. 2. Chair and Department of Environmental Medicine and Epidemiology, Medical University of Silesia in Katowice
Grzegorz Słomian
Oncology Department with Hematological Subdivision, Provincial Specialist Hospital No. 3 in Rybnik

Abstract

Clear cell sarcoma (CCS) is a rare soft-tissue sarcoma and is characterized by a translocation t(12;22) (q13;q12). Because of some similarities to maligned melanoma it is called melanoma of soft parts. CCS has characteristic clinical features. It is commonly reported in young adults as slowly growing tumor followed by aggressive course. Its features are: regional lymph node spread and tendency for local recurrence and a propensity for pulmonary metastasis. Metastatic CCS is a very aggressive disease with pure prognosis. Conventional chemotherapy has little role to play in the management of CCS. The article presents the case of a patient with metastatic CCS with massive lung dissemination, metastatic in liver, left adrenal, pelvis and superficial soft tissue. In patient pazopanib therapy resulted in nine-month control of the disease.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Article Details

How to Cite
1.
Kryszczyszyn-Musialik K, Słomian G. Pazopanib in clear cell sarcoma therapy. OncoReview [Internet]. 2018Mar.14 [cited 2024Nov.23];8(1(29):24-7. Available from: https://journalsmededu.pl/index.php/OncoReview/article/view/418
Issue
Vol 8 No 1(29) (2018)
Section
QUALITY OF LIFE IN ONCOLOGY
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Copyright: © Medical Education sp. z o.o. This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.

Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)

References

1. Rutkowski P, Nowecki ZI. Mięsaki tkanek miękkich. Medical Tribune Polska, Warszawa 2009: 247-249.
2. Jeziorski A. Biblioteka chirurga onkologa. Tom 3. Mięsaki tkanek miękkich. Rutkowski P. (ed). Via Medica, Gdańsk 2015: 217-221.
3. Sara AS, Evans HI, Benjamin RS. Malignant melanoma of soft parts (clear cell sarcoma): study of 30 cases. Cancer 1990; 65: 367-374.
4. Jones RL, Constantinidou A, Thway K et al. Chemotherapy in clear cell sarcoma. Med Oncol 2011; 28: 859-863.
5. Deenik W, Mooi WJ, Rutgers EJ et al. Clear cell sarcoma (malignant melanoma) of soft parts: clinicopathologic study of 30 cases. Cancer 1999; 86: 969-975.
6. Hisaoka M, Ishida T, Kuo TT et al. Clear cell sarcoma of soft tissue: a clinicopathologic, immunohistochemical and molecular analysis of 33 cases. Am J Surg Pathol 2008; 32: 452-460.
7. Kawai A, Hosono A, Nakayama R et al. Clear cell sarcoma of tendons and aponeuroses: a study of 75 patients. Cancer 2007; 109: 109-116.
8. van Akkoi AC, Verhoef C, van Geel AN et al. Sentinel node biopsy for clear cell sarcoma. Eur J Surg Oncol 2006; 32: 996-999.
9. van der Graaf WT, Blay JY, Chawla SP et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2012; 379: 1879-1886.
10. Kumar R, Knick VB, Rudolph SK et al. Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity. Mol Cancer Ther 2007; 6: 2012-2021.
11. Kuiper DR, Hoekstra HJ, Vet RP et al. The management of clear cell sarcoma. EJSO 2003; 29: 568-570.
12. Mackey SL, Hebe J, Cobb MW. Melanoma of the soft parts (clear cell sarcoma): a case report and review of the literature. J Am Acad Dermatol 1998; 38: 815-819.
13. Clark MA, Johnson MB, Thway K et al. Clear cell sarcoma (melanoma of soft parts): The Royal Marsden Hospital experience. Eur J Surg Oncol 2008; 34(7): 800-804.
14. Wagner AJ, Goldberg JM, Dubois SG et al. Tivantinib (ARQ 197), a selective inhibitor of MET, in patients with microphthalmia transcription factor-associated tumors: results of a multicenter phase 2 trial. Cancer 2012; 118: 5894-5902.
15. Liu S, Cheng H, Kwan W et al. Histone deacetylase inhibitors induce growth arrest, apoptosis and differentiation in clear cell sarcoma models. Mol Cancer Ther 2008; 7: 1751-1761.
16. Yokoyama S, Feige E, Poling LL et al. Pharmacologic suppression of MITE expression via HADAC inhibitors in the melanocyte lineage. Pigment Cell Melanoma Res 2008; 21: 457-463.
17. Outani H, Tanaka T, Wakamatsu T et al. Establishment of a novel clear cell sarcoma cell line (Hewga-CCS), and investigation of the antitumor effects of pazopanib on Hewga-CCS. BMC Cancer 2014; 14: 455.
18. Domagała-Haduch M, Jasiówka M, Nowak Ł et al. Complications of palliative antiangiogenic therapy in patients with colorectal cancer. OncoReview 2016; 6: 199-204.